Czech National Bank raised its stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 3.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,339 shares of the company's stock after buying an additional 1,270 shares during the quarter. Czech National Bank's holdings in HCA Healthcare were worth $16,220,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Avantax Advisory Services Inc. raised its holdings in shares of HCA Healthcare by 0.4% during the 1st quarter. Avantax Advisory Services Inc. now owns 8,077 shares of the company's stock worth $2,791,000 after buying an additional 32 shares in the last quarter. Glenview Trust co raised its holdings in shares of HCA Healthcare by 2.3% during the 1st quarter. Glenview Trust co now owns 1,451 shares of the company's stock worth $501,000 after buying an additional 32 shares in the last quarter. Horizon Investments LLC raised its holdings in shares of HCA Healthcare by 1.1% during the 1st quarter. Horizon Investments LLC now owns 3,175 shares of the company's stock worth $1,097,000 after buying an additional 33 shares in the last quarter. Catalyst Financial Partners LLC grew its position in HCA Healthcare by 4.3% during the 1st quarter. Catalyst Financial Partners LLC now owns 872 shares of the company's stock worth $301,000 after acquiring an additional 36 shares during the last quarter. Finally, RWA Wealth Partners LLC grew its position in HCA Healthcare by 2.0% during the 1st quarter. RWA Wealth Partners LLC now owns 1,904 shares of the company's stock worth $658,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company's stock.
HCA Healthcare Trading Up 0.2%
Shares of HCA traded up $1.00 during trading hours on Friday, hitting $402.06. The company had a trading volume of 4,308,470 shares, compared to its average volume of 1,540,330. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $420.98. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. The stock's 50 day moving average price is $384.69 and its 200 day moving average price is $365.16. The firm has a market cap of $94.08 billion, a P/E ratio of 16.90, a P/E/G ratio of 1.26 and a beta of 1.41.
HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, topping analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The firm had revenue of $18.61 billion for the quarter, compared to analysts' expectations of $18.49 billion. During the same period in the previous year, the firm posted $5.50 EPS. The business's revenue for the quarter was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.
HCA Healthcare Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, September 16th. HCA Healthcare's dividend payout ratio is presently 12.11%.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on HCA. Truist Financial boosted their price objective on HCA Healthcare from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Morgan Stanley reduced their price target on HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating on the stock in a research report on Monday, July 28th. Wolfe Research lowered HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research report on Monday, July 28th. Wells Fargo & Company dropped their price objective on HCA Healthcare from $385.00 to $375.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 14th. Finally, Stephens raised HCA Healthcare to a "strong-buy" rating in a research note on Monday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $407.75.
Get Our Latest Analysis on HCA
Insider Buying and Selling at HCA Healthcare
In other news, EVP Michael S. Cuffe sold 3,836 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.
About HCA Healthcare
(
Free Report)
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Featured Articles

Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report